Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China
· Delayed Price · Currency is CNY 58.32
-0.24 (-0.41%)
Apr 30, 2026, 11:30 AM CST
SHA:688621 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Net Income | 201.57 | 210.51 | 177.41 | 184.76 | 156.47 | 105.66 | Upgrade
|
| Depreciation & Amortization | 52.05 | 52.05 | 48.33 | 43.5 | 38.83 | 27.47 | Upgrade
|
| Other Amortization | 19.5 | 19.5 | 20.16 | 20.48 | 14.01 | 5.91 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.65 | -0.65 | - | - | 0.04 | -0 | Upgrade
|
| Asset Writedown & Restructuring Costs | 64.11 | 64.11 | 0.31 | 0.71 | 0.21 | 0.52 | Upgrade
|
| Loss (Gain) From Sale of Investments | -4.97 | -4.97 | 1.82 | -1.29 | -2.62 | -1.68 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 41.68 | 57.77 | 18.66 | 10.47 | Upgrade
|
| Other Operating Activities | -19.93 | 56.17 | 10.31 | 12.68 | 10.64 | 5.12 | Upgrade
|
| Change in Accounts Receivable | -321.2 | -321.2 | -326.37 | -250.51 | -151.92 | -143.04 | Upgrade
|
| Change in Inventory | 1.02 | 1.02 | -0.64 | -1.87 | -4.7 | -1.55 | Upgrade
|
| Change in Accounts Payable | 15.42 | 15.42 | 70.22 | 48.77 | 36.05 | 81.74 | Upgrade
|
| Change in Other Net Operating Assets | 40.66 | 40.66 | 12.98 | - | - | - | Upgrade
|
| Operating Cash Flow | 8.16 | 93.21 | 32.02 | 92.86 | 103.96 | 88.25 | Upgrade
|
| Operating Cash Flow Growth | -77.42% | 191.10% | -65.52% | -10.67% | 17.80% | 40.09% | Upgrade
|
| Capital Expenditures | -41.83 | -42.43 | -30.48 | -72.96 | -103.87 | -84.96 | Upgrade
|
| Sale of Property, Plant & Equipment | 0 | 0 | - | 0 | 0 | 0 | Upgrade
|
| Divestitures | 1.5 | 1.5 | - | - | - | - | Upgrade
|
| Investment in Securities | -129.06 | -167.06 | -40 | -17 | 89.75 | -192.51 | Upgrade
|
| Other Investing Activities | 2.38 | 2.68 | 27.86 | 1.29 | 2.62 | 1.68 | Upgrade
|
| Investing Cash Flow | -167.02 | -205.31 | -42.63 | -88.66 | -11.5 | -275.78 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 216.17 | 148.01 | Upgrade
|
| Long-Term Debt Issued | - | 549.45 | 431.15 | 393.49 | - | - | Upgrade
|
| Total Debt Issued | 421.85 | 549.45 | 431.15 | 393.49 | 216.17 | 148.01 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -153.01 | -33.5 | Upgrade
|
| Long-Term Debt Repaid | - | -379.01 | -439.6 | -237.61 | -11.72 | -16.19 | Upgrade
|
| Total Debt Repaid | -418.21 | -379.01 | -439.6 | -237.61 | -164.72 | -49.69 | Upgrade
|
| Net Debt Issued (Repaid) | 3.63 | 170.44 | -8.44 | 155.88 | 51.45 | 98.32 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 487.55 | Upgrade
|
| Common Dividends Paid | -32.74 | -32.26 | -38.15 | -55.52 | -26.98 | -1.25 | Upgrade
|
| Other Financing Activities | -20.19 | -119.5 | -81.14 | -22.56 | 1.75 | -16.15 | Upgrade
|
| Financing Cash Flow | -49.3 | 18.68 | -127.74 | 77.8 | 26.22 | 568.48 | Upgrade
|
| Net Cash Flow | -208.15 | -93.42 | -138.35 | 82 | 118.68 | 380.95 | Upgrade
|
| Free Cash Flow | -33.67 | 50.78 | 1.54 | 19.9 | 0.09 | 3.29 | Upgrade
|
| Free Cash Flow Growth | - | 3206.74% | -92.28% | 21552.67% | -97.21% | -90.84% | Upgrade
|
| Free Cash Flow Margin | -2.83% | 4.15% | 0.14% | 2.14% | 0.01% | 0.67% | Upgrade
|
| Free Cash Flow Per Share | -0.30 | 0.46 | 0.01 | 0.18 | 0.00 | 0.03 | Upgrade
|
| Cash Income Tax Paid | 37.15 | 38.05 | 65.46 | 41.24 | 32.8 | 12.06 | Upgrade
|
| Levered Free Cash Flow | -167.6 | -45.44 | -54.66 | -53.26 | -49.86 | -26.78 | Upgrade
|
| Unlevered Free Cash Flow | -167.6 | -45.44 | -44.59 | -45.65 | -43.79 | -24.55 | Upgrade
|
| Change in Working Capital | -303.52 | -303.52 | -268.01 | -225.74 | -132.28 | -65.23 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.